iFAST Diagnostics

iFAST Diagnostics

Private
United KingdomHealthcare & Life Scienceshttps://ifastdiagnostics.com/

Last Round

Early Funding

May 28, 2026

Total Funding Raised

$15.25M

Momentum Score

50 /100

Company Overview

iFAST Diagnostics is a biotechnology company that has developed a rapid antimicrobial susceptibility testing (AST) system to provide results in under three hours.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Precision Medicine

Business Model

B2G

Customer Profile

Hardware + Subscription, Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

antimicrobial susceptibility testingASTrapid diagnosticsantimicrobial resistanceAMRsepsis diagnosticsimpedance flow cytometrymicrofluidicsin-vitro diagnosticsIVDsuperbug detectionphenotypic ASTsame-shift diagnosticsminimum inhibitory concentrationMICdiagnostic consumablesrazor and blade model

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iFAST Diagnostics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

iFAST Diagnostics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early FundingMay 28, 2026
SeedNov 5, 2024
Pre SeedFeb 16, 2023

Key People

Founding team and executive leadership

Toby King

Chief Executive Officer

Executive Team

iFAST Diagnostics Investors

Notable investors and investment history

InvestorRounds
OKG CapitalEarly Funding
QantXSeed, Early Funding, Pre Seed
Cambridge Capital GroupEarly Funding
Raw VenturesSeed, Early Funding
UK Innovation & Science Seed FundPre Seed, Seed
Kadmos CapitalPre Seed, Seed
Meridian Health VenturesPre Seed, Seed, Early Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 28, 2026

    $6.35M raised, led by Meridian Health Ventures.

  • May 16, 2026

    Monthly visitors grew 33% MoM.

iFAST Diagnostics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

iFAST Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about iFAST Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersUnited Kingdom
Employee Range16
Year Founded2022
Last FundingMay 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.